Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director Paul Anderson sits down with Proactive’s Tylah Tully to discuss the company’s quarterly results. Record revenue has been recorded for the second consecutive quarter, reaching A$2.03 million for the three months to September 30, 2024, a 7.82% increase on the previous quarter. The growth is attributed to strong demand for its flagship products, Striate+™ and Remplir™. Striate+, used for dental bone regeneration, is available in major markets including the US, Canada and Europe, while Remplir, focused on peripheral nerve repair, is sold in Australia and New Zealand, with global expansion planned. Orthocell is also preparing for the anticipated US Food and Drug Administration (FDA) approval of Remplir, which would give the company access to the US nerve repair market, valued at more than US$1.6 billion. FDA approval is expected by early 2025. Combined, Striate+ and Remplir are projected to tap into a global market worth more than US$4 billion. Orthocell’s partnerships with BioHorizons and Device Technologies have contributed to revenue growth and the company holds A$18.4 million in cash reserves to support its expansion plans. Anderson emphasised the company's potential for exponential growth and its goal to capture a significant share of the global market. #ProactiveInvestors #Orthocell #ASX #RecordRevenue, #MedicalTechnology, #RegenerativeMedicine, #DentalBoneRegeneration, #NerveRepair, #StriatePlus, #Remplir, #GlobalExpansion, #USMarket, #FDAApproval, #MarketGrowth, #SurgeonDemand, #RevenueGrowth, #BioHorizons, #DeviceTechnologies, #HealthcareInnovation, #USFDASubmission, #ClinicalPerformance, #CEOStatement #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews